Skip to main content
Equibles

HCM · HUTCHMED (China) Ltd

Track HCM — free

Use HCM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research HCM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$14.31 +0.11 (+0.77%)
Rebalance outlook locked
Market Cap
$2.42B
Shares
173.81M
Volume · Oct 5 65.13K Avg daily vol (3M) 67.59K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$14.20 Open$14.31 Day$14.10–14.34 52W close$9.99–16.39 Avg vol 30d85K Short int230K · 0.1% float · 1.8d Short vol39% Last earningsJul 30, 2026 DataJan 2020–Oct 2026

Up next

Next earnings call
Jan 28, 2027 Est · unconfirmed · in 16 wks
Q4 2025 earnings call transcript
call held Mar 5, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
-0.3%
Year over year
Operating margin
-7.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-3.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.2%
Year over year · more shares
Price change (1Y)
-11.9%
Trailing year
Short interest
0.1%
Latest settlement · 1.8 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Moderate
Market backdrop VIX 15.3 · calm Equity put/call 0.58
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +7%
above
Price vs 50-day avg +11%
above
RSI (14) 57
neutral
MACD trend Negative
52-week position 66%
mid-range
Momentum
relative strength
Weak
1-month return +1%
trailing
6-month return −7%
trailing
YTD return +7%
this year
Relative strength −19%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $13 › 200d $13 — 200d above 50d
Institutional flow Accumulating
+4% holders QoQ · +8 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.13% of float · ▲ +14.4% MoM · 1.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
56 holders — mid 3-yr range
Squeeze score 41
elevated · 0–100
Fundamentals
Strong
Revenue growth +20%
Y/Y
EPS growth +1200%
Y/Y
Free cash flow $-78.8M
Balance sheet $21.8M
net debt
Quant / Vol
risk profile
Moderate
Volatility 38%
annualized · 1-yr
Max drawdown −39%
past year
ATR 3.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Jun 30, 2020
Innovation Platform operating loss · full year $180M – $200M
Net cash burn · full year $140M – $160M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+7% Bullish
Price vs 50-day avg
+11% Bullish
RSI (14)
57 Neutral
MACD trend
Negative Bearish
52-week position
66% Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $13 › 200d $13 — 200d above 50d
Institutional flow Accumulating
+4% holders QoQ · +8 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.13% of float · ▲ +14.4% MoM · 1.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
56 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $10 Now $14 · 66% Range high $16
vs 200-day avg +7% vs 50-day avg +11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
HCM
HUTCHMED (China) Ltd
this stock
$2.42B +6.5% +19.7% — 0.1%
TAK
Takeda Pharmaceutical Co Ltd
 $60.23B +14.6% — — 0.1%
GALDY
Galderma Group AG/ADR
 $46.00B -6.5% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
 $45.67B +26.7% +4.3% 64.3 2.7%
HLN
Haleon plc
 $40.72B -13.0% — — 0.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
56
% held
2.5%
Net QoQ
+51.8K sh
Top holder
SCHRODER INVESTMENT MANAG…
Held Float
View
Held by Funds
Fund positions
19
View
Short & Settlement
Short Interest Rising
Shares short
230.0K
Days to cover
1.8d
Change
+29.0K sh
View
Short Volume
Short vol %
39%
As of
Oct 2, 2026
Short Total
View
Fails to Deliver
FTD shares
1.5K
Value
$19.6K
As of
Sep 14, 2026
View
Off-Exchange
Off-exchange %
49.5%
Week of
Aug 31, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$548.5M
Net income (FY)
$456.9M
EPS diluted
$0.52
View
Filings
SEC Filings
Latest
6-K
Filed
Sep 29, 2026
This year
34
View
Earnings & Events
Webcasts
Last webcast
Jul 30, 2026
View

Performance

5D 20D 120D MTD YTD
HCM +1.9% +0.6% -7.1% -2.9% +6.5%
SPY -0.2% -0.5% +12.2% +0.9% +12.9%
vs SPY +2.1% +1.1% -19.3% -3.9% -6.3%
Key facts CIK 1648257 CUSIP 44842L103 13F (30d) 1 filings 1 filers Visit website Investor relations